Decreased astrocytosis in brains of high-dose treated mice.

<p>Anti-GFAP antibody (brown) and hematoxylin (blue) staining in A) whole brain and B) enlargement showing thalamus. For comparison, similar staining is presented from an aged matched negative control animal that was mock-infected with a 1% homogenate of normal mouse brain. For this analysis, regions of brain not present in all sections were removed (including cerebellum, brainstem, and olfactory bulb). Scale bars = 200 μm. Levels of GFAP staining are shown for C) whole brain, D) hippocamus, and E) thalamus. The high-dose-treated mice showed a trend of less GFAP accumulation in the brain compared to mock-treated mice (<i>p</i> = 0.103 by a 2 sample <i>t</i>-test on the logarithms of the levels), whereas no difference was detected between the low-dose-treated and mock infected mice (<i>p</i> = 0.906 again by a 2 sample <i>t</i>-test). Decreases in high-dose treated verses mock-treated mice were most pronounced in the thalamus (<i>p</i> = 0.000557 by a 2 sample <i>t</i>-test); no significant differences in staining were seen amongst groups in the hippocampus (<i>p</i> = 0.825 for the high-dose group compared to the mock treated group and <i>p</i> = 0.839 for the low-dose group compared to the mock treated group, again with a 2 sample <i>t</i>-test).